Adipokines as immunometabolic bridges: Linking obesity susceptibility, periodontal disease, hypertension, and systemic health

While periodontitis is a well-recognized oral health challenge, its impact extends far beyond the local periodontium through a complex, bidirectional relationship with systemic metabolic disorders, particularly obesity and hypertension. Central to this interchange are adipokines—bioactive cytokines and hormones secreted by adipose tissue that function as active endocrine signaling molecules regulating energy metabolism, vascular tone, and immune responses.^1,2 When adipose tissue is metabolically healthy, it secretes protective, anti-inflammatory adipokines—most notably adiponectin—that promote vascular relaxation, support insulin sensitivity, and suppress pro-inflammatory signaling.^3,4

In obesity and metabolic dysfunction, expanded visceral fat shifts toward an altered secretory profile dominated by high circulating levels of pro-inflammatory adipokines, including leptin, resistin, and visfatin (also known as NAMPT).⁴ Leptin and resistin activate intracellular signaling cascades, like nuclear Factor-B (NF-B), which continuously stimulate immune cells to release pro-inflammatory cytokines like tumor necrosis factor-alpha (TNF-), interleukin-1 beta (IL-1β) and interleukin-6 (IL-6). Simultaneously, the loss of adiponectin removes a vital “brake” on systemic inflammation, downregulating endothelial nitric oxide synthase (eNOS) and driving vascular stiffness, essential hypertension, insulin resistance, and heightened osteoclast activity throughout the body. When chronic localized infections like periodontitis overlap with this systemic adipokine dysregulation, these signaling molecules act as molecular bridges that amplify tissue destruction both locally in the oral cavity and systemically within the cardiovascular network. Epidemiological and clinical evidence demonstrates a strong association between excess body fat and heightened susceptibility to periodontal disease.^5,6 Obesity influences the onset, severity, and progression of periodontitis through several distinct biological mechanisms.

Hyperinflammatory immune priming

Hypertrophic visceral adipose tissue releases baseline elevations of pro-inflammatory cytokines, including TNF- and IL-6. This systemic low-grade inflammation primes circulating neutrophils and monocytes. When exposed to subgingival bacterial plaque, these hyperreactive immune cells release excessive amounts of reactive oxygen species (ROS) and matrix metalloproteinases (MMPs), accelerating the destruction of the periodontal ligament and surrounding alveolar bone.^7-9

Dysregulation of the oral microbiome

Obesity alters host salivary composition, local immune responses, and nutrient availability in the gingival crevicular fluid (GCF), creating a microenvironment that favors periodontal pathogens.⁶ Individuals with obesity show an increased abundance of red-complex periodontal pathogens: Porphyromonas gingivalis, Tannerella forsythia, and Treponema denticola, compared to lean individuals.¹⁰

Impaired periodontal healing and tissue repair

Obesity-induced oxidative stress and local gingival insulin resistance impair microvascular blood flow within periodontal tissues.3 This compromised microcirculation reduces the delivery of essential nutrients and immune clearance mechanisms needed for tissue regeneration, making obese individuals less responsive to standard nonsurgical periodontal treatments

In periodontitis, local periodontal destruction is driven by an exaggerated host immune response to dysbiotic subgingival biofilms. GCF contains cytokines, MMPs, adipokines, and other inflammatory mediators that are being investigated as diagnostic and prognostic biomarkers of periodontal activity.¹¹ Measurement of adipokines in gingival GCF demonstrates a direct correlation with clinical attachment loss and periodontal pocket depth.³ Elevated levels of leptin and visfatin in inflamed gingival tissue stimulate gingival fibroblasts and osteoblasts to upregulate matrix MMPs and pro-inflammatory cytokines TNF-, IL-1, and IL-6. In addition, elevated visfatin and leptin increase the ratio of receptor activator of nuclear factor-B ligand (RANKL) to osteoprotegerin (OPG), accelerating osteoclast differentiation and alveolar bone loss.³ Under normal <a href="https://healthylife7.com/glp-1s-help-patients-lose-weight-but-obesity-is-still-a-chronic-condition/” title=”GLP-1s help patients lose weight, but obesity is still a chronic condition”>conditions, adiponectin inhibits NF-B activation, suppresses RANKL, and promotes bone-protective OPG production. In individuals with obesity or severe periodontitis, circulating and local GCF levels of adiponectin are significantly decreased, removing an essential protective brake on periodontal breakdown.³

The biological crosstalk between periodontal disease, obesity, and essential hypertension is driven by systemic endotoxemia, altered adipokine dynamics, and endothelial dysfunction.⁶ Ulcerated periodontal pockets allow periodontal pathogens and lipopolysaccharides (LPS) to enter the systemic circulation. This bacteremia reinforces adipose tissue inflammation, enhancing the release of pro-inflammatory adipokines. Elevated circulating leptin, resistin, and visfatin downregulate endothelial eNOS activity, reducing nitric oxide (NO) bioavailability. The loss of NO impairs vascular relaxation, increases arterial stiffness, and elevates total peripheral resistance.When leptin levels rise in the bloodstream, the hormone travels to the brain and binds to receptors in the hypothalamus. This triggers a surge in sympathetic nervous system activity—the body’s fight-or-flight response. This chronic sympathetic overdrive causes blood vessels in the kidneys to constrict while simultaneously prompting the renal tubules to reabsorb more sodium. Together, the narrowed blood vessels and fluid retention directly drive up arterial blood pressure.

Adipokines are an immunometabolic bridge connecting obesity, periodontal disease, and systemic cardiovascular conditions. In obesity, visceral fat expansion drives chronic systemic inflammation, microvascular impairment, and oral dysbiosis—heightening host susceptibility to periodontitis. In turn, the resulting adipokine imbalance exacerbates local tissue destruction in the oral cavity while simultaneously promoting systemic endothelial dysfunction, arterial stiffness, and essential hypertension.

Once again, these shared inflammatory mechanisms highlight the need for interdisciplinary care between oral health professionals and medical providers. Targeted periodontal interventions, like nonsurgical periodontal therapy, have been shown to significantly lower circulating pro-inflammatory adipokines, elevate protective serum adiponectin levels, and reduce overall systemic inflammatory strain.³

Beyond treatment, evaluating adipokine levels in saliva or gingival crevicular fluid GCF offers a novel, noninvasive diagnostic avenue for early cardiovascular risk screening in patients with overlapping metabolic and periodontal disease. Translating these salivary insights into routine dental practice relies on rapid point-of-care technologies, where microfluidic “Lab-on-a-Chip” platforms—like the bead-based cassette systems pioneered by Dr. John McDevitt’s team at UT Austin and NYU or the Integrated Microfluidic Platform for Oral Diagnostics (IMPOD) developed at UC Berkeley and Sandia National Laboratories—can quantify salivary markers like C-reactive protein, interleukin-6, and active tissue-breakdown enzymes within minutes. These academic breakthroughs are moving into clinical workflows through commercial innovators and emerging biosensor startups adapting electrochemical test strips to read salivary markers chairside. Ultimately, addressing oral health and metabolic dysregulation concurrently is essential for comprehensive, preventive cardiovascular medicine.

Editor’s note: This article first appeared in RDH eVillage newsletter, a publication of the Endeavor Business Media Dental Group. Read more articles and subscribe

References

1. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11(2):85-97. doi:10.1038/nri2921
2. Okamoto Y, Kihara S, Ouchi N, et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2002;106(22):2767-2770. doi:10.1161/01.cir.0000042707.50032.19
3. Checa-Ros A, Hsueh WC, Merck B, González-Torres H, Bermúdez V, D’Marco L. Obesity and oral health: the link between adipokines and periodontitis. touchREV Endocrinol. 2024;20(1):25-31. doi:10.17925/EE.2024.20.1.7
4. Khan MS, Alasqah M, Alammar LM, Alkhaibari Y. Obesity and periodontal disease: a review. J Family Med Prim Care. 2020;9(6):2650-2653. doi:10.4103/jfmpc.jfmpc_283_20
5. Kim CM, Lee S, Hwang W, et al. Obesity and periodontitis: a systematic review and updated meta-analysis. Front Endocrinol (Lausanne). 2022;13:999455. doi:10.3389/fendo.2022.999455
6. Reytor-González C, Parise-Vasco JM, González N, et al. Obesity and periodontitis: a comprehensive review of their interconnected pathophysiology and clinical implications. Front Nutr. 2024;11:1440216. doi:10.3389/fnut.2024.1440216
7. Matthews JB, Wright HJ, Roberts A, Ling-Mountford N. Cooper PR, Chapple ILC. Neutrophil hyper-responsiveness in periodontitis. J Dent Res.2007;86(8):718-722. doi:10.1177/154405910708600806
8. Chapple ILC, Matthews JB. The role of reactive oxygen and antioxidant species in periodontal tissue destruction. Periodontol 2000.2007;43:160-232. doi:10.1111/j.1600-0757.2006.00178.x
9. Franco C, Hernández-Ríos P, Sorsa T, Biguetti C, Hernández M. Matrix metalloproteinases as regulators of periodontal inflammation. Int J Mol Sci.2017;18(2):440. doi:10.3390/ijms18020440
10. Suresh S, Mahendra J, Kumar ARP, Singh G, Jayaraman S, Paul R. Comparative analysis of subgingival red complex bacteria in obese and normal weight subjects with and without chronic periodontitis. J Indian Soc Periodontol. 2017;21(3):186-191. doi:10.4103/jisp.jisp_241_17
11. Barros SP, Williams R, Offenbacher S, Morelli T. Gingival crevicular fluid as a source of biomarkers for periodontitis. Periodontol 2000. 2016;70(1):53-64. doi:10.1111/prd.12107